Business Standard

Pricing trend, launches, stability of growth boosters for Dr Reddy's

Near-term outlook and valuation are expected to support the stock price

Dr Reddy’s, Labs
Premium

Ram Prasad Sahu
Dr Reddy's, India's third-largest listed pharmaceutical company by market capitalisation, posted a steady performance for the December quarter. Barring Europe, which saw a decline, most key markets posted YoY growth in the quarter, leading to 8 per cent growth in consolidated revenues. 

Among the top performers were the emerging markets, which reported a 20 per cent jump; the proprietary business gained 37 per cent. Within emerging markets, the rest of the world segment saw sharp 46 per cent growth aided by product launches and higher sales volumes for the base business. The emerging markets business of Dr Reddy’s is the second-largest

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jan 30 2022 | 11:12 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com